MAP3K7/MAP3K7IP1(TAK1)
Sign in to save this workspaceUniProt MAP3K7:O43318; TAB1:Q15750 · PDB · AlphaFold · Substrate: Casein · Clone: full-length MAP3K7; aa 437-504 MAP3K7IPI
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 92.6% | 7.4% | 78.23 | 0.534 |
| 2 | Sunitinib | 77.8% | 22.2% | 91.73 | 0.524 |
| 3 | Gilteritinib | 76.8% | 23.2% | 88.97 | 0.506 |
| 4 | Midostaurin | 74.2% | 25.8% | 78.64 | 0.500 |
| 5 | Nintedanib | 67.6% | 32.4% | 90.23 | 0.608 |
| 6 | Ripretinib | 52.8% | 47.2% | 92.95 | 0.674 |
| 7 | Pacritinib | 43.2% | 56.8% | 88.64 | 0.452 |
| 8 | Defactinib | 42.5% | 57.5% | 92.68 | 0.450 |
| 9 | Abrocitinib | 34.7% | 65.3% | 99.50 | 0.581 |
| 10 | Abemaciclib | 33.1% | 66.9% | 91.48 | 0.563 |
| 11 | Sorafenib | 28.2% | 71.8% | 96.72 | 0.776 |
| 12 | Bosutinib | 26.8% | 73.2% | 87.22 | 0.555 |
| 13 | Regorafenib | 25.7% | 74.3% | 95.99 | 0.719 |
| 14 | Dabrafenib | 20.3% | 79.7% | 94.74 | 0.633 |
| 15 | Osimertinib | 18.7% | 81.3% | 97.24 | 0.733 |
| 16 | Crizotinib | 15.4% | 84.6% | 91.39 | 0.581 |
| 17 | Pazopanib | 15.3% | 84.7% | 97.49 | 0.672 |
| 18 | Tofacitinib | 14.8% | 85.2% | 99.25 | 0.684 |
| 19 | Zanubrutinib | 14.4% | 85.6% | 98.24 | 0.788 |
| 20 | Brigatinib | 14.0% | 86.0% | 82.96 | 0.513 |
Paralog block
No paralog group registered for this kinase.
EMT expression
Not in the EMT expression panel.
Selectivity landscape vs inhibition on MAP3K7/MAP3K7IP1
Each point is one of the 92 approved drugs; color = inhibition % on MAP3K7/MAP3K7IP1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…